Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data – The Cancer Letter

OS Therapies Inc. announced positive data from a phase IIb clinical trial (NCT04974008) of OST-HER2 (OST31-164)—the company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or […]

Read the full article here

Source: cancerletter.com

Categories: Oncologists1, General Medicine News

Tweets with this article

The Cancer Letter

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data. Phase IIb clinical trial by @OSTherapies. https://t.co/dGNmFgLQs4

Program Guide – ASCO Meeting Program Guide

Jonathan Strosberg H. Lee Moffitt Cancer Center and Research Institute Jonathan Strosberg , Anna Koumarianou , Rachel Riechelmann , Jorge Hernando , Sara Cingarlini ,…

MoffittCancerCenter January 23, 2025

Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer

Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.

OncLive.com January 23, 2025

Chadi Nabhan: Why I wrote a book about cancer – The Cancer Letter

Almost all of us who have practiced oncology for years have encountered situations where we have had to counsel caregivers and guide them throughout their…

chadi nabhan MD, MBA January 23, 2025

Overview of the DESTINY-Breast12 Study

Panelists discuss the findings from the DESTINY-Breast12 study, focusing on the efficacy and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and its…

Targeted Oncology January 23, 2025

Cancer Incidence Continues to Rise, Especially in Women Younger Than 65

Of note, lung cancer incidence was higher among women younger than 65 compared with their male counterparts in 2021.

Cancer Network January 23, 2025

Glucarpidase improves recovery after chemotherapy-induced kidney toxicity

Glucarpidase significantly improved kidney function for patients who developed acute kidney injury from high-dose methotrexate, according to results of a large, multicenter observational study.Glucarpidase (Voraxaze,…

HemOnc Today January 23, 2025

First-Line Tislelizumab Plus Chemo Elicits Deep Responses Linked to OS Benefits in ESCC

OS benefits with tislelizumab plus chemotherapy were comparable between early and late responders in the phase 3 RATIONALE-306 study in patients with ESCC.

OncLive.com January 23, 2025

JNCCN 360 – Advanced Skin Cancers – Mehran Yusuf, MD, on Treating Merkel Cell Carcinoma: A Radiation Oncology Perspective

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…

Journal of the @NCCN January 23, 2025

Honoring Excellence: Q and A with Dr. Cassandra Fritz of the Washington University in St. Louis Internal Medicine Residency Program

A Q and A with Dr. Cassandra Fritz from the WashU internal medicine program. The program is receiving a 2025 ACGME Barbara Ross-Lee, DO DEI…

Washington U. Med January 23, 2025

AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients

Discover emerging themes and early-stage clinical oncology pipelines at the second AACR Oncology Industry Partnership event.

AACR January 23, 2025

Related Articles